MedTrace Logo

Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction

NCT05462730 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2026-03-27

Study results available
· View outcomes & findings →

Summary

The overall primary objective of the PULSE-MI trial is to test the hypothesis that administration of single-dose glucocorticoid pulse therapy in the pre-hospital setting reduces final infarct size in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI)

Conditions

  • ST Elevation Myocardial Infarction
  • Inflammatory Response
  • Myocardial Reperfusion Injury
  • Myocardial Injury

Interventions

DRUG

Methylprednisolone

A dosis of 250 mg methylprednisolone is suspended in isotonic saline to a total volume of 4 mL prior to infusion.

DRUG

Isotonic saline

A bolus infusion of 4 mL isotonic saline (NaCl 0.9%).

Sponsors & Collaborators

  • Thomas Engstrom

    lead OTHER

Principal Investigators

  • Jacob T Lønborg, MD, DMSc · Rigshospitalet, Denmark

  • Jasmine M Madsen, MD · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-14
Primary Completion
2024-01-30
Completion
2024-10-17

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05462730 on ClinicalTrials.gov